What Is Alamandine? Definition and What Research Reports

Definition

Alamandine is a naturally occurring heptapeptide (a seven-amino-acid peptide) of the renin-angiotensin system, described in the literature as a member of the angiotensin peptide family that acts through the Mas-related G protein-coupled receptor member D (MrgD) rather than through the classical angiotensin II type 1 receptor. It was introduced to the field as a newly identified angiotensin family member in a 2014 review in Current Opinion in Nephrology and Hypertension (PMID 24389733), and subsequent reviews grouped it with angiotensin-(1-7) inside what researchers have called the "protective arm" or counter-regulatory arm of the renin-angiotensin system (PMID 31245374). In practical terms, when a paper refers to alamandine it is referring to this specific endogenous peptide and, almost always, to its interaction with MrgD in a cell-culture or animal model.

What Class of Molecule It Is and Where It Comes From

Alamandine is an endogenous signalling peptide, not a synthetic analogue designed from scratch. Reviews of the angiotensin A/alamandine/MrgD axis described its formation from angiotensin A, and also by decarboxylation of the N-terminal aspartate residue of angiotensin-(1-7), placing it downstream of the same enzymatic cascade that generates other protective angiotensin fragments (PMID 27447621). A comparative review in Pharmacological Research set out the similarities and differences between angiotensin-(1-7) and alamandine, noting that the two peptides are closely related in structure yet engage distinct receptors (PMID 27456244).

That receptor distinction is the defining feature of the term. Angiotensin-(1-7) is generally described as acting at the Mas receptor, while alamandine has been characterised as pairing with MrgD (PMID 31245374). Many of the experimental papers below used MrgD blockade or knockdown to test whether an observed effect depended on that receptor.

How the Term Is Used in Peptide Research

In the published literature, "alamandine" appears in three broad ways:

• As an endogenous mediator. Papers measure or discuss the peptide as part of the renin-angiotensin system's counter-regulatory signalling, alongside ACE2 and angiotensin-(1-7) (PMID 27447621).
• As an experimental tool compound. Investigators apply it to cultured cells or administer it to animals to probe MrgD-dependent pathways, as in a reperfusion-injury study that tested whether cardiac protection required the MrgD receptor (PMID 29998915).
• As a hypothesised therapeutic target. Review articles have framed the axis as a candidate for cardiovascular and fibrotic disease, including a 2022 Peptides review that discussed alamandine in the context of fibrosis (PMID 35931236).

Quick Reference

What the Published Literature Reports

Fibrosis and fibroblast activation

A 2022 review in Peptides surveyed preclinical work and positioned alamandine as a candidate anti-fibrotic mediator within the renin-angiotensin system (PMID 35931236). A mechanistic study published in the Journal of Translational Medicine in 2023 reported that the alamandine/MrgD axis prevented TGF-β1-mediated fibroblast activation, and the study attributed that effect to regulation of aerobic glycolysis and mitophagy (PMID 36635651). Together these papers illustrate the typical shape of the evidence base: a proposed mechanism tested in cells, with reviews summarising the direction of travel rather than clinical outcomes.

Vascular and cardiac models

A 2025 paper in Atherosclerosis reported that alamandine suppressed vascular calcification through inhibition of ferroptosis, an iron-dependent form of regulated cell death (PMID 41110386). In an earlier experiment published in Circulation Journal, researchers reported that alamandine protected the heart against reperfusion injury and that the effect was mediated via the MrgD receptor (PMID 29998915). A 2018 review in Current Hypertension Reports collected findings on angiotensin-(1-7) and alamandine across experimental models of hypertension and atherosclerosis (PMID 29541937).

Pulmonary and ocular models

A 2024 study in Fundamental and Clinical Pharmacology compared two agents in monocrotaline-induced pulmonary arterial hypertension and reported that alamandine and, to a greater degree, melatonin attenuated the induced hypertension in that model (PMID 39128482). Separately, a 2025 report in the Journal of Zhejiang University Science B stated that alamandine inhibited pathological retinal neovascularization by targeting the MrgD-mediated HIF-1α/VEGF pathway (PMID 41116209).

Hypothesis-generating commentary

Because ACE2 sits upstream of both angiotensin-(1-7) and alamandine, some commentary extended the axis to viral illness. A 2021 article in the Journal of the Renin-Angiotensin-Aldosterone System discussed potential protective effects of alamandine in patients with SARS-CoV-2 (PMID 34853605). Readers should note the difference in evidence weight between that kind of mechanistic proposal and a controlled experiment.

Adverse Events: What Studies Report

The papers cited on this page are preclinical studies and narrative reviews; none of them is presented as a human safety trial, and they do not establish a tolerability profile, a therapeutic window or long-term outcomes for alamandine in people. Reviews that grouped alamandine with angiotensin-(1-7) framed both peptides as counter-regulatory elements of the renin-angiotensin system and discussed unresolved questions about receptor pharmacology rather than documented human harms (PMID 27456244, PMID 31245374). Where an animal study reported an effect, such as attenuation of monocrotaline-induced pulmonary arterial hypertension, that finding applied to the model and species studied and was not a statement about human safety (PMID 39128482).

Regulatory and Research Status

Alamandine is not an approved drug product in the United States or the European Union. It appears in the scientific record as an endogenous peptide and as a research chemical used in laboratory investigation, and material sold for laboratory work is typically labelled research use only, meaning it is not intended for diagnostic or therapeutic application in humans. Nothing in the cited literature supports a clinical role, and the reviews themselves describe the axis as an emerging area of pathophysiology rather than settled therapy (PMID 27447621, PMID 35931236).

How to Read This Entry

Three points follow from the evidence above. First, the term alamandine is specific: it names one peptide and, by convention, its MrgD-linked signalling, so a paper describing "the alamandine axis" is describing receptor-level biology, not a product. Second, the effects summarised here were reported in cells and rodents; the direction of an effect in a monocrotaline or calcification model does not transfer automatically to human physiology. Third, several of the strongest mechanistic claims, including the glycolysis and mitophagy findings, came from single studies that had not been replicated in the literature cited on this page (PMID 36635651).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before making any decision related to a medical condition or a substance discussed here.

References

• Alamandine: a new member of the angiotensin family (Current Opinion in Nephrology and Hypertension, 2014)
• Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology (International Journal of Molecular Sciences, 2016)
• Angiotensin (1-7) and Alamandine: Similarities and differences (Pharmacological Research, 2016)
• Angiotensin-(1-7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis (Current Hypertension Reports, 2018)
• Alamandine Protects the Heart Against Reperfusion Injury via the MrgD Receptor (Circulation Journal, 2018)
• Alamandine and Its Receptor MrgD Pair Up to Join the Protective Arm of the Renin-Angiotensin System (Frontiers in Medicine, 2019)
• Alamandine: Potential Protective Effects in SARS-CoV-2 Patients (Journal of the Renin-Angiotensin-Aldosterone System, 2021)
• Alamandine: A promising treatment for fibrosis (Peptides, 2022)
• Alamandine/MrgD axis prevents TGF-β1-mediated fibroblast activation via regulation of aerobic glycolysis and mitophagy (Journal of Translational Medicine, 2023)
• Alamandin and especially melatonin attenuate pulmonary arterial hypertension induced by monocrotalin (Fundamental and Clinical Pharmacology, 2024)
• Alamandine suppresses vascular calcification through inhibition of ferroptosis (Atherosclerosis, 2025)
• Alamandine inhibits pathological retinal neovascularization by targeting the MrgD-mediated HIF-1α/VEGF pathway (Journal of Zhejiang University Science B, 2025)